ES2337537A1 - Food preparation and pharmaceutical composition containing an embryonic extract - Google Patents
Food preparation and pharmaceutical composition containing an embryonic extract Download PDFInfo
- Publication number
- ES2337537A1 ES2337537A1 ES200800802A ES200800802A ES2337537A1 ES 2337537 A1 ES2337537 A1 ES 2337537A1 ES 200800802 A ES200800802 A ES 200800802A ES 200800802 A ES200800802 A ES 200800802A ES 2337537 A1 ES2337537 A1 ES 2337537A1
- Authority
- ES
- Spain
- Prior art keywords
- preparation
- embryonic
- food
- pharmaceutical composition
- egg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 title claims abstract description 12
- 235000013305 food Nutrition 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 210000001647 gastrula Anatomy 0.000 claims abstract description 7
- 201000004384 Alopecia Diseases 0.000 claims abstract description 5
- 230000013020 embryo development Effects 0.000 claims abstract description 5
- 230000003676 hair loss Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 239000013543 active substance Substances 0.000 claims abstract description 3
- 230000001796 anti-degenerative effect Effects 0.000 claims abstract description 3
- 208000024963 hair loss Diseases 0.000 claims abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 claims abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 235000013601 eggs Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000282326 Felis catus Species 0.000 claims description 5
- 210000002969 egg yolk Anatomy 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000007123 defense Effects 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000003071 parasitic effect Effects 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000004554 Leishmaniasis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 210000000991 chicken egg Anatomy 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940111782 egg extract Drugs 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 210000002023 somite Anatomy 0.000 description 3
- 230000003867 tiredness Effects 0.000 description 3
- 208000016255 tiredness Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/08—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from eggs
-
- A23L1/30—
-
- A23L1/32—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Preparado alimenticio y composición farmacéutica que contiene un extracto embrionario y sus respectivos usos.Food preparation and pharmaceutical composition It contains an embryonic extract and its respective uses.
Preparado alimenticio y composición farmacéutica que contiene un extracto embrionario y sus respectivos usos.Food preparation and pharmaceutical composition It contains an embryonic extract and its respective uses.
Es sabido que durante el periodo de organogénesis celular, ciertas sustancias reguladoras evitan la multiplicación ilimitada de las células típica del desarrollo de ciertas enfermedades, tales como el cáncer.It is known that during the period of cellular organogenesis, certain regulatory substances prevent unlimited multiplication of cells typical of the development of certain diseases, such as cancer.
Este hecho ha motivado que se realicen experimentos para determinar los efectos de los tejidos embrionarios homogeneizados en el crecimiento y diseminación de tumores.This fact has motivated them to be carried out. experiments to determine the effects of embryonic tissues homogenized in the growth and spread of tumors.
Siguiendo esta línea de investigación, se han dado a conocer preparados destinados a la prevención y tratamiento de cáncer cuyo principio activo son extractos embrionarios tomados en etapas específicas del desarrollo embrionario.Following this line of research, they have released preparations for prevention and treatment of cancer whose active substance are embryonic extracts taken in specific stages of embryonic development.
A modo de ejemplo, se destacan los documentos CA 2197050 y WO 9811905 que describen respectivos preparados que contienen extractos de huevos de gallina fertilizados, que han sido incubados de forma preferida de entre aproximadamente 8 y aproximadamente 10 días, y extractos embrionarios de huevos de trucha, en una etapa de desarrollo de 5 a 20 somites.As an example, CA documents stand out 2197050 and WO 9811905 describing respective preparations that they contain fertilized chicken egg extracts, which have been preferably incubated between about 8 and approximately 10 days, and embryonic egg extracts from trout, in a development stage of 5 to 20 somites.
El solicitante ha podido comprobar que la administración de extractos de embriones tomados en una etapa anterior a las etapas de extracción hasta la fecha utilizadas, y muy específica del desarrollo embrionario, tiene efectos sorprendentemente revitalizadores previsiblemente relacionados con un efecto significativo en el ritmo de las divisiones celulares.The applicant has been able to verify that the administration of embryo extracts taken at one stage prior to the extraction stages to date used, and very specific to embryonic development, it has effects surprisingly revitalizers predictably related to a significant effect on the rhythm of cell divisions.
Para ello, el germen embrionario debe obtenerse previamente a la formación de masas segmentadas de tejido mesodérmico, o somites, en el desarrollo embrionario, pero una vez completada la fase blástula. En concreto, el germen embrionario es obtenido en el preparado alimenticio de la invención cuando se han desarrollado las tres hojas embrionarias ectoblasto-mesoblasto-entoblasto en un huevo fecundado e incubado durante un periodo específico, con lo que el preparado alimenticio comprende al menos un germen embrionario en fase final de gástrula.For this, the embryonic germ must be obtained prior to the formation of segmented tissue masses mesodermal, or somites, in embryonic development, but once the blastula phase completed. Specifically, the embryonic germ is obtained in the food preparation of the invention when they have been developed the three embryonic leaves ectoblasto-mesoblasto-entoblasto in an egg fertilized and incubated during a specific period, with that the food preparation comprises at least one germ embryonic in the final phase of the gastrula.
Según otra característica del preparado según la invención, el germen embrionario es extraído de un huevo de gallina durante el periodo comprendido entre las 18 y las 30 horas posteriores a su incubación.According to another characteristic of the preparation according to the invention, the embryonic germ is extracted from a chicken egg during the period between 18 and 30 hours after incubation.
De acuerdo a una variante de obtención, el preparado además comprende parte de la yema del huevo aspirada durante la extracción del germen por aspiración.According to a variant of obtaining, the prepared also includes part of the egg yolk aspirated during the extraction of the germ by aspiration.
De forma preferida, el preparado es congelado para su conservación y posterior administración vía oral.Preferably, the preparation is frozen for conservation and subsequent oral administration.
La administración del preparado en humanos es indicado como regenerador en caso de sequedad de piel o caída de pelos.Administration of the preparation in humans is indicated as regenerative in case of dry skin or fall of hairs
La administración del preparado en animales es indicado como vitalizador y estimulante de las defensas en caso de padecer de enfermedades infecciosas o parasitarias como Leishmaniosis en perros o inmunodeficiencias víricas en gatos.The administration of the preparation in animals is indicated as vitalizer and stimulant of defenses in case of suffer from infectious or parasitic diseases such as Leishmaniasis in dogs or viral immunodeficiencies in cats.
Según otro aspecto de la invención, se da a conocer una composición farmacéutica que contiene como sustancia activa al menos un extracto embrionario en la etapa de desarrollo embrionario de final de gástrula extraído de un huevo fecundado e incubado.According to another aspect of the invention, it is given to know a pharmaceutical composition that contains as a substance activate at least one embryonic extract in the development stage embryonic end of gastrula extracted from a fertilized egg e incubated
La composición está destinada para su uso en tratamientos antidegenerativos, para tratar artrosis, cirrosis, nefritis o procesos neurodegenerativos.The composition is intended for use in antidegenerative treatments, to treat osteoarthritis, cirrhosis, Nephritis or neurodegenerative processes.
La composición está también destinada para su uso en tratamientos regenerativos en mamíferos.The composition is also intended for use in regenerative treatments in mammals.
Según otra aplicación, la composición está destinada para su uso como coadyuvante de tratamientos contra el cáncer, tales como radioterapia y quimioterapia.According to another application, the composition is intended for use as an adjunct to treatments against cancer, such as radiotherapy and chemotherapy.
A continuación se describe un ejemplo de obtención de al menos un germen embrionario para el preparado alimenticio según la invención.An example of obtaining at least one embryonic germ for the preparation food according to the invention.
Se extrae un huevo de gallina fecundado de una incubadora tras un plazo comprendido entre las 18 y las 36 horas posteriores a su incubación. Así se consigue un germen embrionario en fase final de gástrula, previo a la formación de somites. El contenido obtenido tras la rotura de la cáscara, formado por la yema y la clara, es depositado posteriormente en una bandeja estéril.A fertilized chicken egg is extracted from a incubator after a period between 18 and 36 hours after incubation. Thus an embryonic germ is achieved in the final phase of the gastrula, prior to the formation of somites. He content obtained after the breakage of the shell, formed by the yolk and the clear one, is deposited later in a sterile tray.
Seguidamente, se agita la yema balanceando la bandeja hasta que el germen embrionario se sitúa en una posición dorsal y centrada. En dicha posición, se procede a la aspiración de dicho germen embrionario que queda contenido junto con la yema circundante en una cantidad de volumen aproximadamente entre 0,5 y 2 ml, según la aspiración realizada. Para la mencionada aspiración se utiliza, de un modo en si conocido, una jeringa estéril, émbolo o pipeta.Next, the yolk is shaken by balancing the tray until the embryonic germ is placed in a position Dorsal and centered. In this position, the aspiration of said embryonic germ that is contained along with the yolk surrounding in an amount of volume approximately between 0.5 and 2 ml, according to the aspiration performed. For the mentioned aspiration, use, in a manner known per se, a sterile syringe, plunger or pipette.
Previamente a su administración, se procede a su congelación para su almacenaje y en el momento de su uso tiene que ser descongelado. Aún así, puede administrarse directamente sin el proceso de congelación.Prior to administration, proceed to your freezing for storage and at the time of use has to be defrosted Even so, it can be administered directly without the freezing process
Posteriormente a dicha explicación de obtención de dicho preparado se explicarán varios ejemplos prácticos con distintos usuarios, primeramente se explican dos casos en animales y a continuación otros dos casos en pacientes humanos.After said explanation of obtaining of this preparation several practical examples will be explained with different users, first two cases are explained in animals and then two other cases in human patients.
En un paciente felino macho y de raza europea de 16 años de edad y con 4 Kg de peso que estaba aquejado de anorexia, caquexia, nefritis crónica y dolor generalizado, se empezó un tratamiento a base del preparado según la invención. Se administraba una dosis de 1 ml de extracto diario. Al cabo de dos semanas recuperó el apetito, desapareciendo el dolor y normalizándose todas las constantes vitales y ganando peso hasta los 5,5 kg actuales después de tres años de inicio del tratamiento. En este caso, la esperanza de vida de dicho paciente supera largamente a la media del más del 20%.In a male and European feline patient of 16 years old and with 4 kg of weight that was suffering from anorexia, cachexia, chronic nephritis and generalized pain, a treatment based on the preparation according to the invention. It was administered a dose of 1 ml of daily extract. After two weeks he recovered his appetite, the pain disappearing and all normalized the vital signs and gaining weight up to the current 5.5 kg after three years of initiation of treatment. In this case, the life expectancy of said patient exceeds the average of the more than 20%
En otro paciente, en este caso un perro de raza boxer macho de 9 años de edad que estaba afectado de leishmaniosis y tumores malignos, además de someter al paciente a una operación y a un tratamiento de leishmaniosis con la medicación pertinente, se le aplicó una dosis de extracto de huevo según la invención a razón de 2 ml dos veces al día. A día de hoy, tras tres años, no ha presentado recidivas de los tumores y ha superado la leishmaniosis, siendo su calidad de vida óptima.In another patient, in this case a dog of breed 9-year-old male boxer who was affected by leishmaniosis and malignant tumors, in addition to subjecting the patient to an operation and to a leishmaniasis treatment with the relevant medication, you will be applied a dose of egg extract according to the invention at the rate of 2 ml twice a day. Today, after three years, it has not presented recurrences of the tumors and has overcome leishmaniosis, being its optimum quality of life.
En un paciente humano, un varón de 41 años, que estaba afectado de calvicie, prostatitis, cansancio, colesterolemia, taquicardia y hipertensión arterial, se empezó un tratamiento a base del preparado según la invención. Se administraba una dosis de 2 ml tres veces al día, empezándose a observar a los seis meses de inicio del tratamiento crecimiento folicular, normalización de síntomas prostéticos, normalización del ritmo cardíaco y la tensión arterial. Al cabo de 5 años se puede constatar que se ha mejorado la calidad de vida de dicho paciente.In a human patient, a 41-year-old male, who I was affected by baldness, prostatitis, tiredness, cholesterolemia, tachycardia and arterial hypertension, a treatment based on of the preparation according to the invention. A dose of 2 ml was administered three times a day, beginning to observe at six months of onset of follicle growth treatment, symptom normalization prosthetics, normalization of heart rate and blood pressure. After 5 years it can be seen that the quality has been improved of life of said patient.
En otro paciente humano, en este caso una mujer de 39 años, afectada de cáncer con metástasis varias desde hace nueve años, en tratamiento de quimioterapia y radioterapia, se empezó a administrar el tratamiento a razón de 2 ml con nueve dosis diarias. Se lleva aplicando dicho tratamiento en dicha paciente desde hace cinco meses y se ha observado una mejora sustancial de la calidad de vida, aumentando la resistencia al cansancio, aumento de la vitabilidad y capacidad física.In another human patient, in this case a woman 39, affected by cancer with several metastases for several years nine years, in chemotherapy and radiotherapy treatment, began to administer the treatment at a rate of 2 ml with nine doses daily It is carried out by applying said treatment in said patient for five months and a substantial improvement in the quality of life, increasing fatigue resistance, increasing Vitability and physical capacity.
Después de estos ejemplos descritos, se ha realizado una muestra global para estudiar los resultados. En dicha muestra de estudio comprendida por animales, 15 perros y 2 gatos, y ocho humanos, se ha podido concluir que no se producen efectos perniciosos o secundarios. En concreto, a continuación se exponen los resultados obtenidos.After these described examples, it has been conducted a global sample to study the results. In bliss study sample comprised of animals, 15 dogs and 2 cats, and eight humans, it has been concluded that there are no effects pernicious or secondary. Specifically, they are exposed below The results obtained.
A nivel animal:At the animal level:
En tres de los perros de la muestra, afectados de leishmaniosis, se observa clínica y analíticamente una aumento de la capacidad regenerativa en la medula del hueso, los glóbulos rojos y blancos. En general, mejora la calidad de vida, con lo que un perro que tenga nefritis se cura y supera la insuficiencia renal.In three of the dogs in the sample, affected of leishmaniasis, an increase of regenerative capacity in the bone marrow, red blood cells and whites. In general, it improves the quality of life, bringing a dog with nephritis heals and overcomes insufficiency renal.
En otros tres perros de la muestra, afectados de hepatitis, se observa que superan la enfermedad sin dejar secuelas.In three other dogs in the sample, affected by hepatitis, it is observed that they overcome the disease without leaving aftermath.
En otro de los perros, afectado de hipotiroidismo, con la administración de dicho extracto de huevo, le permite disminuir la dosis de tiroxina a la mitad a medida que la glándula se está activando.In another of the dogs, affected by hypothyroidism, with the administration of said egg extract, you allows you to reduce the dose of thyroxine in half as the Gland is activating.
En cinco de los perros, afectados de artrosis y un estado caquéctico, se mejora su estado anímico y su esperanza de vida, superándola en un 20%.In five of the dogs, affected by osteoarthritis and a cachectic state, your mood is improved and your hope of life, surpassing it by 20%.
En tres de los perros de la muestra, afectados de cáncer, se mejora su calidad de vida sin perdida de peso, aumentando su esperanza de vida.In three of the dogs in the sample, affected of cancer, your quality of life is improved without weight loss, Increasing your life expectancy.
En un gato de los de la muestra, afectado de nefritis, se estabiliza la enfermedad y se incrementa su esperanza de vida, superándola en un 30%.In a cat of the sample, affected by nephritis, the disease is stabilized and your hope is increased of life, surpassing it by 30%.
En el otro gato de la muestra, afectado de encefalitis con ataques de epilepsia diarios, después del tratamiento con el extracto de huevo se disminuyen los ataques hasta valores de tan sólo un ataque al mes.In the other cat in the sample, affected by encephalitis with daily epilepsy attacks, after treatment with egg extract attacks are reduced until values of only one attack per month.
A nivel de humanos:At the human level:
En uno de los pacientes humanos de la muestra, afectado de cansancio, dolor de extremidades y calvicie progresiva, se observa post-tratamiento la desaparición de todos los síntomas de fatiga y se produce un crecimiento folicular en el paciente.In one of the human patients in the sample, affected by fatigue, limb pain and progressive baldness, post-treatment is observed the disappearance of all fatigue symptoms and follicular growth occurs in the patient.
En otro paciente femenino de 70 años de edad, afectada de alergia, dolor gástrico y pérdida de pelo, se observa una desaparición de todos los síntomas y una mejora del estado general del paciente.In another 70-year-old female patient, affected by allergy, gastric pain and hair loss, it is observed a disappearance of all symptoms and an improvement of the state General of the patient.
En otro paciente humano, afectado de cáncer pulmonar y metástasis con tratamiento de quimioterapia, se observa, posteriormente al tratamiento, una mejora general que produce una mayor vitalidad del individuo.In another human patient, affected by cancer pulmonary and metastasis with chemotherapy treatment, it is observed, after treatment, a general improvement that produces a greater vitality of the individual.
En otro paciente, afectado de una fractura de fémur no consolidada que le ha producido perdida de masa muscular y resistencia al movimiento, se observa una mejora en el movimiento y un aumento de la fuerza muscular.In another patient, affected by a fracture of unconsolidated femur that has caused loss of muscle mass and resistance to movement, an improvement in movement and A muscular strength increase.
En un paciente, afectado de una inflamación de la mucosa intestinal que le produce dolor abdominal, se observa que mejoran los síntomas con dicho tratamiento.In a patient, affected by an inflammation of the intestinal mucosa that produces abdominal pain, it is observed that Symptoms improve with such treatment.
En otros tres pacientes de más de 60 años, con cansancio, se observa que mejoran los síntomas del cansancio y se aumenta el tono vital.In three other patients over 60 years old, with tiredness, it is observed that the symptoms of tiredness improve and Increases the vital tone.
Destacadamente, conviene mencionar que con la administración de dicho preparado en este tipo de tratamientos no se ha detectado ningún efecto secundario, demostrándose en más de doscientos pacientes su inocuidad.Notably, it is worth mentioning that with the administration of said preparation in this type of treatment is not has detected any side effects, demonstrating in more than Two hundred patients their safety.
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200800802A ES2337537B8 (en) | 2008-03-19 | 2008-03-19 | PREPARED FOOD AND PHARMACEUTICAL COMPOSITION CONTAINING AN EMBRYO EXTRACT AND ITS RESPECTIVE USES. |
PCT/EP2009/052764 WO2009115429A1 (en) | 2008-03-19 | 2009-03-10 | Food preparation and pharmaceutical composition containing an embryonic extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200800802A ES2337537B8 (en) | 2008-03-19 | 2008-03-19 | PREPARED FOOD AND PHARMACEUTICAL COMPOSITION CONTAINING AN EMBRYO EXTRACT AND ITS RESPECTIVE USES. |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2337537A1 true ES2337537A1 (en) | 2010-04-26 |
ES2337537B2 ES2337537B2 (en) | 2011-02-02 |
ES2337537B8 ES2337537B8 (en) | 2011-08-01 |
Family
ID=40833510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200800802A Expired - Fee Related ES2337537B8 (en) | 2008-03-19 | 2008-03-19 | PREPARED FOOD AND PHARMACEUTICAL COMPOSITION CONTAINING AN EMBRYO EXTRACT AND ITS RESPECTIVE USES. |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2337537B8 (en) |
WO (1) | WO2009115429A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR086437A1 (en) * | 2011-10-13 | 2013-12-11 | Aixela Juan Cunill | PREPARED EGG WITH REGENERATING, ANALGESIC AND / OR ANTI-INFLAMMATORY PROPERTIES |
ITMI20120008A1 (en) * | 2012-01-04 | 2013-07-05 | Biava Maura | COMPOSITIONS WITH ANTI-NEURODEGENERATIVE ACTIVITY |
ES2604552B1 (en) * | 2017-01-19 | 2017-09-13 | Liofilizados Girona, S.L. | Egg preparation with anti-inflammatory and antioxidant properties |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888172A (en) * | 1982-09-23 | 1989-12-19 | Alfaceu Corporation | Pharmaceutical for treating tumors and methods for making it |
WO1998011905A1 (en) * | 1996-09-20 | 1998-03-26 | Adriana Carluccio | Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process |
CA2197050A1 (en) * | 1997-02-07 | 1998-08-07 | Morton P. Shulman | Anti-cancer agents derived from fertilized incubated shell eggs |
EP1374703A1 (en) * | 2002-06-20 | 2004-01-02 | Pier Mario Biava | Use of a non-human animal embryo extract for the preparation of a nutritive substance and a dietetic-nutraceutical supplement |
WO2007020222A2 (en) * | 2005-08-12 | 2007-02-22 | Steel S.R.L. | Pharmaceutical composition containing as active substance a protein fraction extracted from oviparous embryos at the cell differentiation stage and preparation process thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4400640A1 (en) * | 1994-01-12 | 1995-07-13 | Eftag Entstaubung Foerdertech | Diagnosis and treatment of malignant tumours |
FR2778850A1 (en) * | 1998-05-22 | 1999-11-26 | Jacques Vincent Cavaille | Composition for retarding aging of mammals |
US20070275036A1 (en) * | 2006-05-18 | 2007-11-29 | Celldyne Biopharma, Llc | Avian follistatin product |
-
2008
- 2008-03-19 ES ES200800802A patent/ES2337537B8/en not_active Expired - Fee Related
-
2009
- 2009-03-10 WO PCT/EP2009/052764 patent/WO2009115429A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888172A (en) * | 1982-09-23 | 1989-12-19 | Alfaceu Corporation | Pharmaceutical for treating tumors and methods for making it |
WO1998011905A1 (en) * | 1996-09-20 | 1998-03-26 | Adriana Carluccio | Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process |
CA2197050A1 (en) * | 1997-02-07 | 1998-08-07 | Morton P. Shulman | Anti-cancer agents derived from fertilized incubated shell eggs |
EP1374703A1 (en) * | 2002-06-20 | 2004-01-02 | Pier Mario Biava | Use of a non-human animal embryo extract for the preparation of a nutritive substance and a dietetic-nutraceutical supplement |
WO2007020222A2 (en) * | 2005-08-12 | 2007-02-22 | Steel S.R.L. | Pharmaceutical composition containing as active substance a protein fraction extracted from oviparous embryos at the cell differentiation stage and preparation process thereof |
Non-Patent Citations (2)
Title |
---|
MIHAESCU, G., et al. Significant modification of lipid metabolism in aged persons following the treatment with a nutritive supplement containing embryonary peptides - preliminary results. Rom. J. Int. Med. 2005, vol. 43, n$^{o}$ 1-2, páginas 133-139. Todo el documento. * |
MIHAESCU, G., et al. Significant modification of lipid metabolism in aged persons following the treatment with a nutritive supplement containing embryonary peptides - preliminary results. Rom. J. Int. Med. 2005, vol. 43, nº 1-2, páginas 133-139. Todo el documento. * |
Also Published As
Publication number | Publication date |
---|---|
ES2337537B8 (en) | 2011-08-01 |
WO2009115429A1 (en) | 2009-09-24 |
ES2337537B2 (en) | 2011-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102461681B1 (en) | Pharmaceutical and food composition for treating or alleviating influenza a | |
ES2337537B2 (en) | PREPARED FOOD AND PHARMACEUTICAL COMPOSITION CONTAINING AN EMBRYO EXTRACT AND ITS RESPECTIVE USES. | |
WO2005067948A2 (en) | Biological medicine for treating various diseases caused by various virus, bacterial infection | |
RU2585049C2 (en) | Preparation from eggs with regenerative, analgesic and anti-inflammatory properties | |
RU2519221C1 (en) | Biologically active composition for improvement of sexual function in men (versions) | |
KR102077833B1 (en) | Fuctional food compositions | |
US10959450B2 (en) | Food composition for relieving symptoms of allergic and autoimmune diseases | |
Marlani et al. | Arechaatechu L. seed and Anredera cordifolia (Ten) Steenis leaf powder supplementation reduced serum transaminase in laying hens | |
CN104069062B (en) | Hilicidum injection for preventing and treating ischemic cardiovascular and cerebrovascular diseases as well as preparation method and application thereof | |
CN103432425B (en) | Medicinal preparation for treating tetanus of animals | |
RU2744919C1 (en) | Remedy for the treatment of endometritis in cows | |
Rowland | Veterinary care of bearded dragons | |
Tripathi | Pharmaceutical from Animals | |
RU2709144C1 (en) | Method for treating dyspepsia of calves | |
Lennox | Antonius Guainerius on epilepsy | |
RU2329791C2 (en) | Method of hemopoiesis stimulation associated with dogs' acute radiation sickness | |
RU2572215C1 (en) | Therapeutic and energetic agent for animals | |
Mironidou-Tzouveleki et al. | Effects of extracts of marine algae on osteoporosis | |
RU2310462C1 (en) | Method for treating and preventing inflammatory diseases of reproductive organs in cows | |
CN105832714B (en) | Application of taurine in preventing and/or treating diseases caused by coronavirus and/or rotavirus viruses | |
WO2023242599A1 (en) | A benzimidazole compound with antihelminthic activity for use in reversing, arresting or slowing down cellular ageing in a vertebrate subject | |
Thoresen | Symphytum officinale: Common Comfrey | |
CN115120604A (en) | Application of apigenin 7-O-glucoside as preparation for reducing uric acid and gouty arthritis | |
KR101491914B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising the extract of Euonymi lignum suberalatu | |
TR2023002511A1 (en) | HOMEOPATHIC MEDICINE CONTAINING NOSODE OBTAINED FROM LIPEDEMA TISSUE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20100426 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2337537 Country of ref document: ES Kind code of ref document: B2 Effective date: 20110121 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20180924 |